Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
Immunotherapy combo extends life in advanced endometrial cancer
A meta-analysis of 4,052 patients from RCTs found that adding PD-1/PD-L1 inhibitors to chemotherapy improved overall survival (median 43.7 v…
Adding immunotherapy to chemo boosted survival by over 14 months in advanced endometrial cancer, a new analysis finds.
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer
New meta-analysis shows PD-1 inhibitors improve response rates for dMMR colorectal cancer
This meta-analysis of 1460 patients with dMMR/MSI-H metastatic colorectal cancer found that PD-1/PD-L1 monotherapy significantly improved ob…
A large review of 1460 patients found PD-1 inhibitors significantly improved tumor response rates compared to chemotherapy for dMMR colorect…
Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancer
New analysis shows dual immune therapy helps patients with advanced lung cancer live longer and delays disease growth
This meta-analysis evaluates dual immune checkpoint inhibitor therapy versus control treatments in patients with advanced or metastatic non-…
A large review of 6,369 patients found that using two immune checkpoint drugs together improved survival time compared to standard treatment…
Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors
Subcutaneous shots match intravenous drugs for cancer survival and response rates in solid tumors
This systematic review and meta-analysis of 1243 patients with solid tumors found no significant difference in overall survival, progression…
A large review found that giving cancer drugs under the skin works just as well as the traditional vein injection for patients with solid tu…
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 show improved risk discrimination for immune-toxicity-associated systemic injury
New Tool Predicts Immune Drug Organ Damage
This translational multicohort study evaluated patients receiving immune checkpoint inhibitors in United States electronic health record dat…
A new system helps doctors predict which patients might suffer dangerous organ injury from powerful cancer drugs, giving them time to act so…
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…